Home Infusion Therapy: IV Medications and Administration at Home

Delivering intravenous medication outside a hospital or infusion center is no longer a workaround — it's a well-established clinical service covering antibiotics, chemotherapy support agents, hydration therapy, nutritional support, and pain management. Home infusion therapy allows patients who require IV or injectable drugs to receive treatment in their own homes, typically under the supervision of a registered nurse and in coordination with a licensed pharmacy. The scope is broader than most people expect, and the logistics are more structured than they might look from the outside.

Definition and scope

Home infusion therapy is the preparation, delivery, and clinical administration of intravenous, subcutaneous, or epidural medications in a non-institutional setting. The National Home Infusion Association (NHIA) defines home infusion as a service requiring the integrated work of a licensed pharmacy, skilled nursing, and medical direction — distinguishing it from simple medication delivery.

The therapy encompasses a wide range of drug categories:

1. Anti-infectives — IV antibiotics such as vancomycin, ceftriaxone, and daptomycin, frequently ordered after hospital discharge for infections including endocarditis, osteomyelitis, and cellulitis
2. Parenteral nutrition — total parenteral nutrition (TPN) or partial parenteral nutrition for patients unable to absorb adequate calories through the gastrointestinal tract
3. Immunoglobulin therapy (IVIG/SCIG) — for immune deficiency disorders, including primary immunodeficiency diseases affecting roughly 1 in 1,200 Americans, according to the Immune Deficiency Foundation
4. Biologic and specialty agents — infliximab for Crohn's disease and rheumatoid arthritis, natalizumab for multiple sclerosis, and similar agents requiring controlled infusion rates
5. Hydration therapy — IV fluids for chronic conditions causing persistent dehydration
6. Pain management — epidural or intrathecal analgesia via programmable pump for cancer pain or complex post-surgical cases

The types of home care services that co-exist alongside home infusion — including wound care, monitoring, and medication management — often appear in the same patient episode, making coordination between disciplines a practical necessity rather than a nicety.

How it works

A home infusion episode typically begins with a physician order and a referral to an accredited home infusion pharmacy. That pharmacy compounds or dispenses the medication, verifies compatibility, and coordinates delivery of all supplies — IV bags, tubing, an infusion pump if required, and any ancillary equipment. The pharmacy also employs or contracts clinical pharmacists who monitor lab values and drug levels throughout therapy.

The nursing component follows a parallel track. A skilled nursing at home visit is required for initial catheter assessment, patient or caregiver training, and periodic clinical monitoring. For long-term IV antibiotics — commonly running 4 to 6 weeks — most patients eventually manage their own infusions between nursing visits, following a training protocol verified by the nurse.

Vascular access is the clinical centerpiece. Access types span:

• Peripheral IV — short-term use, typically under 7 days, suitable for non-vesicant drugs
• PICC line (peripherally inserted central catheter) — the most common access for home infusion, placed by a vascular access nurse and confirmed by imaging before use
• Tunneled central catheter (e.g., Hickman, Broviac) — for long-term therapy or parenteral nutrition extending beyond 90 days
• Implanted port — surgically placed, accessed by non-coring needle, preferred for intermittent therapy such as monthly biologic infusions

Accreditation matters here. ACHC (Accreditation Commission for Health Care) and URAC both offer home infusion-specific accreditation standards covering pharmacy operations, nursing protocols, and patient education — standards that Medicare and most commercial payers use to qualify providers.

Common scenarios

The post-surgical home care population generates a significant share of home infusion referrals. Joint replacement patients with periprosthetic infection, for example, routinely receive 6 weeks of IV antibiotics following surgical debridement — a therapy course that would otherwise require an extended inpatient or skilled nursing facility stay.

Patients managing chronic conditions represent another large cohort. Crohn's disease treated with biologic infusions, primary immune deficiency maintained on subcutaneous immunoglobulin, and heart failure patients receiving periodic IV diuresis all fall under a home infusion framework rather than standard home health.

Oncology-adjacent therapy — anti-nausea agents, hydration, and some supportive biologics — has expanded home infusion into palliative care at home settings where the goal is comfort and function maintenance rather than curative treatment. The distinction matters for insurance authorization and for the kind of home care assessments and care plans the clinical team will build.

Decision boundaries

Home infusion is appropriate when the patient is medically stable enough that the drug's primary risk lies in the infusion itself — reactions, line complications, lab drift — rather than in acute physiological instability requiring continuous monitoring.

Three factors typically determine whether home infusion is safe and viable:

1. Caregiver capacity — a reliable adult able to respond to complications, assist with pump operation, and reach clinical staff if needed. This is a real threshold; some patients with no caregiver available are not candidates.
2. Home environment — refrigeration for temperature-sensitive drugs, a clean workspace for line care, and reliable phone or internet access for telehealth check-ins (covered further in the context of technology in home care)
3. Insurance authorization — Medicare Part B covers certain home infusion drugs and the professional services under specific conditions established by the 21st Century Cures Act; Medicare coverage for home infusion nursing was formalized beginning in 2021 under medicare coverage for home care rules that distinguish the pharmacy benefit from the nursing benefit

The contrast with inpatient or infusion center care is not primarily about clinical risk tolerance — it's about infrastructure. A patient receiving vancomycin at home and a patient receiving vancomycin in a hospital bed are getting the same drug at the same dose, monitored against the same lab parameters. The difference is who draws the trough level, who assesses the PICC site, and who handles the 2 a.m. pump alarm. When those responsibilities are clearly assigned and trained, the clinical gap closes substantially.